A Study on the Safety of Deucravacitinib Exposure in Pregnant Women and Their Offspring

Study Summary

This observational study aims to assess pregnancy and infant outcomes among pregnant women with psoriasis who have been exposed to deucravacitinib treatment in the USA.

Conditions

Psoriasis

Interventions / Drugs

Deucravacitinib Systemic psoriasis medications No systemic medications

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment833 participants

Primary Completion—

Lead SponsorBristol-Myers Squibb

Data Retrieved2026-04-11 04:08:14.745678+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.